TTLL12

Across TCGA pan-cancer cohorts, TTLL12 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of TTLL12’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where TTLL12 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TTLL12 is over-expressed in tumor, although a few such as HNSC show the opposite, repressed pattern.

CCRCC, HNSC, and PDAC are the cancer types where TTLL12 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TTLL12 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	III,IV	+0.258	<.001	11	view →
HNSC	All	III,IV	−0.251	.001	11	view →
PDAC	Female	III,IV	+0.718	<.001	9	view →
LSCC	Male	II,III,IV	+0.576	<.001	8	view →
COAD	Female	All	+0.189	<.001	7	view →
LUAD	All	All	+0.089	.015	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

TTLL12–CCRCC

Open the CCRCC breakdown →